Ninety percent of non-Hodgkin-lymphomas are of B-cell phenotype. The availability of monoclonal antibodies in their treatment is of fundamental importance. Rituximab was the first monoclonal antibody approved by the FDA. Rituximab is a monoclonal antibody against the CD20 antigen, approved by the FDA originally for the treatment of relapsing or refractory low grade (indolent) or follicular non-Hodgkin-lymphoma. Nevertheless, rituximab achieved its most basic success not in follicular lymphoma, but - when combined with chemotherapy- in diffuse large B-cell lymphoma. Since the availability of rituximab, treatment results have improved in virtually all B-cell lymphoma subtypes. Conjugation of the antiCD20 monoclonal antibody with a radioisotope is a step by which not only the CD20+ tumor cells, but also the neighbouring CD20- negative tumour cells are destructed. Ibritumomab tiuxetan (Zevalin) has been approved originally for relapsing or treatmentresistant follicular lymphoma, but now it can be given already as consolidation treatment following remission induction in previously untreated follicular lymphoma patients as well. Chronic lymphocytic leukemia belongs to the low grade non-Hodgkin-lymphomas. In this disorder prognosis greatly depends on the intrinsic genetical characteristics of the disease. Treatment with purine nucleoside analogues certainly is a step forward as compared with alkylating agents, but these drugs did not improve overall survival. Monoclonal antibodies open a new era in the treatment of CLL patients. Alemtuzumab (monoclonal anti-CD52 antibody) is suitable for the treatment of those CLL patients, whose disease is resistant to purin nucleoside analogues because of certain genetical characteristics of the disease. According to the newest results completion of the standard fludarabin-cytoxan chemotherapy with rituximab offers survival advantage for our CLL patients.
|Translated title of the contribution||Monoclonal antibodies in the treatment of non-Hodgkin-lymphomas|
|Number of pages||10|
|Publication status||Published - Dec 1 2009|
ASJC Scopus subject areas